TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR

Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation. 

ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for surgery. The speakers summarise the trial design, the enrolled population, and the key safety and clinical outcomes observed through two years of follow-up. 

Overall, the procedure proved feasible and safe in this challenging cohort, with results at up to 24 months that clinicians found encouraging. Christopher Allen and Raj Makkar also discuss patient selection, procedural nuances, and how a transcatheter option for native AR could change treatment pathways for patients who are poor surgical candidates.

This interview was filmed at PCR London Valves 2025: see more videos here.